Evidence map›Paper›PMID 37399435›Full record

ArticleBMJ open2023

Use of a targeted, computer/web-based guided self-help psychoeducation toolkit for distressing hallucinations (MUSE) in people with an at-risk mental state for psychosis: protocol for a randomised controlled feasibility trial.

Jahnese Hamilton, Bronia Arnott, Charlotte Aynsworth, Nicola A Barclay, Lauren Birkett, Toby Brandon, Lyndsey Dixon, Robert Dudley, J Einbeck, Christopher Gibbs and 4 more

Abstract readClinical Trial Protocol
In one paragraph

Article in BMJ open, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Jahnese HamiltonResearch and Development, Cumbria Northumberland Tyne and Wear NHS Foundation Trust, Newcastle upon Tyne, UK jahnese.hamilton@cntw.nhs.uk.ORCID 0000-0003-1783-5648
Bronia ArnottFaculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.
Charlotte AynsworthResearch and Development, Cumbria Northumberland Tyne and Wear NHS Foundation Trust, Newcastle upon Tyne, UK.
Nicola A BarclayCentral At-Risk Mental State Service, Cumbria Northumberland Tyne and Wear NHS Foundation Trust, Newcastle upon Tyne, UK.
Lauren BirkettResearch and Development, Cumbria Northumberland Tyne and Wear NHS Foundation Trust, Newcastle upon Tyne, UK.
Toby BrandonFaculty of Health and Life Sciences, Northumbria University, Newcastle upon Tyne, UK.
Lyndsey DixonResearch and Development, Cumbria Northumberland Tyne and Wear NHS Foundation Trust, Newcastle upon Tyne, UK.
Robert DudleyResearch and Development, Cumbria Northumberland Tyne and Wear NHS Foundation Trust, Newcastle upon Tyne, UK.
J EinbeckDepartment of Psychology, Durham University, Durham, UK.
Christopher GibbsResearch and Development, Cumbria Northumberland Tyne and Wear NHS Foundation Trust, Newcastle upon Tyne, UK.
Ehsan KharatikoopaeiDepartment of Psychology, Durham University, Durham, UK.
Jennifer SimpsonEarly Intervention in Psychosis Service, Tees Esk and Wear Valleys NHS Foundation Trust, Darlington, UK.
Guy DodgsonResearch and Development, Cumbria Northumberland Tyne and Wear NHS Foundation Trust, Newcastle upon Tyne, UK.
Charles FernyhoughDepartment of Psychology, Durham University, Durham, UK.

Funding

Wellcome Trust
6 · The paper itself

Abstract

introductionIndividuals who access at-risk mental state (ARMS) services often have unusual sensory experiences and levels of distress that lead them to seek help. The Managing Unusual Sensory Experiences (MUSE) treatment is a brief symptom targeted intervention that draws on psychological explanations to help account for unusual experiences. Practitioners use formulation and behavioural experiments to support individuals to make sense of their experiences and enhance coping strategies. The primary objective of this feasibility trial is to resolve key uncertainties before a definitive trial and inform parameters of a future fully powered trial. METHODS AND ANALYSIS: 88 participants aged 14-35 accepted into ARMS services, experiencing hallucinations/unusual sensory experiences which are considered by the patient to be a key target problem will be recruited from UK National Health Service (NHS) sites and randomised using 1:1 allocation (stratified by site, gender, and age) to either 6-8 sessions of MUSE or time-matched treatment as usual. Participants and therapists will be unblinded, research assessors are blinded. Blinded assessment will occur at baseline, 12 weeks and 20 weeks postrandomisation. Data will be reported in line with Consolidated Standards of Reporting Trials. Primary trial outcomes are feasibility outcomes, primary participant outcomes are functioning and hallucinations. Additional analysis will investigate potential psychological mechanisms and secondary mental well-being outcomes. Trial progression criteria follows signal of efficacy and uses an analytical framework with a traffic-light system to determine viability of a future trial. Subsequent analysis of the NHS England Mental Health Services Data Set 3 years postrandomisation will assess long-term transition to psychosis. ETHICS AND DISSEMINATION: This trial has received Research Ethics Committee approval (Newcastle North Tyneside 1 REC; 23/NE/0032). Participants provide written informed consent; young people provide assent with parental consent. Dissemination will be to ARMS Services, participants, public and patient forums, peer-reviewed publications and conferences. TRIAL REGISTRATION NUMBER: ISRCTN58558617.

Indexed as

AlprostadilPsychotic DisordersAdolescentComputersFeasibility StudiesHallucinationsHumansInternetRandomized Controlled Trials as TopicState MedicineTreatment OutcomeAlprostadilMENTAL HEALTHPSYCHIATRYRandomized Controlled Trial

Identifiers

PMID37399435
PMCPMC10314705

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.